Abstract 1868
Background
In 2016, nivolumab could be prescribed according to French registration in stage IIIB/IV NSCLC after disease progression with prior platinum-based chemotherapy and TKI therapy for patients with EGFR mutation. The Observatory of Drugs, Medical Devices and Therapeutic Innovations (OMEDIT), a network from the Health Ministry has evaluated the use, current practices and medico-economic approach in the Bretagne and Pays de la Loire areas.
Methods
All consenting adult patients with stage IIIB/IV NSCLC who initiated nivolumab (3 mg/kg every 2 weeks) in 2016 were included. Minimum follow-up for survival was 12 months. Sex, age, mutation profile, toxicities, Clinic Benefit (CB: pts with complete/partial response/stable disease as the best response), progression-free survival (PFS) and overall survival (OS) have been studied for ECOG PS 0-1 pts (according to registration).
Results
377 pts with squamous (113 pts), non-squamous (197) and undifferentiated (67) NSCLC have been included. The median number of courses was 8 (1-54). 140 pts (37%) had 1 to 4 courses, 67 pts (18%) 5 to 8 courses and 170 pts (45%) more than 8. 247 pts were treated in 2nd line, 98 in 3rd line. All lines combined, CB was experienced by 212 pts (56%). For these pts, median course was 17 (1-54), mPFS and mOS were 4.6 months and 15.0 months, respectively. No difference on survival has been noticed according to histology, treatment line, age (cut-off 70 y), grade III/IV toxicity. However, mPFS and mOS were lower in ECOG PS ≥ 2 pts than in PS0-1 pts: 2.4 months vs 4.6 m (p < 0.01) for PFS and 3.7 m vs 15.0 m (p < 0.001) for OS. 20% of pts presented grade III/IV toxicities. These pts presented a better CB (74% vs 56%, p = 0.002). In 2016-2017, this treatment, for pts initiated in 2016 only, cost 15.8 million euros (drug, hospitalisation and transportation). 86% of these costs were dedicated to pts who experienced CB.
Conclusions
In a real-life setting, survival outcomes and toxicities with nivolumab in advanced NSCLC are comparable to literature data. ECOG PS ≥ 2 pts presented shorter survival than PS0-1 pts. Interestingly, 86% of the cost incurred for these treatments was to pts with CB. Updated data will be shown at the meeting.
Clinical trial identification
Legal entity responsible for the study
Cancer Observatory, OMEDIT B and PL.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
R. Corre: Board, invitation Congress: BMS. J-Y. Douillard: CMO: ESMO. O. Molinier: Expert advice: BMS. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract